Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRAS | P01112 | 14/20 | 1.00 |
| ▸ | ESR1 | P03372 | 13/20 | 1.00 |
| ▸ | ESR2 | Q92731 | 13/20 | 1.00 |
| ▸ | TOP1 | P11387 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.36 |
| ▸ | ITGB3 | P05106 | 3/20 | 0.36 |
| ▸ | ITGA2B | P08514 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4618436 | 0.99 | HRAS (1.00) | HRASESR1ESR2TOP1KDM4E | |
| SCHEMBL14102117 | 0.99 | HRAS (0.98) | HRASESR1ESR2TOP1KDM4E | |
| SCHEMBL6175307 | 0.93 | HRAS (0.86) | HRASESR1ESR2TOP1KDM4E | |
| SCHEMBL6974763 | 0.92 | HRAS (1.00) | HRASESR1ESR2TOP1KDM4E | |
| Hydrochloric Acid SCHEMBL6974692 | 0.92 | HRAS (1.00) | HRASESR1ESR2TOP1KDM4E | |
| SCHEMBL6178332 | 0.91 | HRAS (0.83) | HRASESR1ESR2TOP1KDM4E | |
| SCHEMBL6974333 | 0.85 | HRAS (1.00) | HRASESR1ESR2TOP1KDM4E | |
| Tallimustine SCHEMBL62279 | 0.85 | HRAS (0.82) | HRASESR1ESR2TOP1KDM4E | |
| Hydrochloric Acid SCHEMBL6976535 | 0.85 | HRAS (1.00) | HRASESR1ESR2TOP1KDM4E | |
| Tallimustine SCHEMBL1230144 | 0.84 | HRAS (0.82) | HRASESR1ESR2TOP1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040259799-A1 | Use of heterocyclic and benzoheterocyclic polyamides structurally related to the natural antibiotic distamycin a for the treatment of beta-thalassaemia | ASSOCIAZIONE VENETA PER LA LOTTA ALLA TALASSEMIA (IT) | 2004-12-23 | — | — | US | claimed |
| EP-0937070-B1 | BENZOHETEROCYCLIC DISTAMYCIN DERIVATIVES, PROCESS FOR PREPARING THEM, AND THEIR USE AS ANTITUMOR AND ANTIVIRAL AGENTS | PHARMACIA ITALIA SPA (IT) | 2003-12-03 | — | — | EP | claimed |
| US-6153642-A | Benzoheterocyclic distamycin derivatives, process for preparing them, and their use as antitumor and antiviral agents | PHARMACIA & UPJOHN S.P.A. (IT) | 2000-11-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259799-A1 | Use of heterocyclic and benzoheterocyclic polyamides structurally related to the natural antibiotic distamycin a for the treatment of beta-thalassaemia | HBZ, HBG2, HBB | HRAS 3056/4885ESR1 4577/4885ESR2 2064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.